Clinical pharmacology of imeglimin for the treatment of type 2 diabetes

References

• Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281.
   PubMed Web of Science ®Google Scholar
• Skyler JS, Bakris GL, Bonifacio E, et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes. 2017;66:241–255.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383:1068–1083.
   PubMed Web of Science ®Google Scholar
• Rask-Madsen C, King GL. Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab. 2013;17:20–33.
   PubMed Web of Science ®Google Scholar
• Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332:73–78.
   PubMed Web of Science ®Google Scholar
• Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet. 2008;371:1800–1809.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S55–S64.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S73–S85.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–1379.
   PubMed Web of Science ®Google Scholar
• Proks P, Reimann F, Green N, et al. Sulfonylurea stimulation of insulin secretion. Diabetes. 2002;51(Suppl 3):S368–376.
   PubMed Web of Science ®Google Scholar
• Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014;35:992–1019.
   PubMed Web of Science ®Google Scholar
• Hinnen D. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectr. 2017;30:202–210.
   PubMedGoogle Scholar
• Hsia DS, Grove O, Cefalu WT. An update on SGLT2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24:73–79.
   PubMedGoogle Scholar
• Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev. 2002;18(Suppl 2):S10–15.
   PubMedGoogle Scholar
• Van De Laar FA, Lucassen PL, Akkermans RP, et al. α-glucosidase inhibitors for patients with type 2 diabetes: results from a cochrane systematic review and meta-analysis. Diabetes Care. 2005;28:154–163.
   PubMed Web of Science ®Google Scholar
• Storgaard H, Gluud LL, Bennett C, et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS ONE. 2016;11:e0166125.
   PubMed Web of Science ®Google Scholar
• Hirst JA, Farmer AJ, Ali R, et al. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care. 2012;35:446–454.
   PubMed Web of Science ®Google Scholar
• Van Gaal L, Scheen A. Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care. 2015;38:1161–1172.
   PubMed Web of Science ®Google Scholar
• Grunberger G. Should side effects influence the selection of antidiabetic therapies in type 2 diabetes? Curr Diab Rep. 2017;17:21.
   PubMed Web of Science ®Google Scholar
• Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf. 2013;12:153–175.
   PubMed Web of Science ®Google Scholar
• Sherifali D, Nerenberg K, Pullenayegum E, et al. The effect of oral antidiabetic agents on A1C levels. Diabetes Care. 2010;33:1859–1864.
   PubMed Web of Science ®Google Scholar
• Poxel. Imeglimin - US/EU [Internet]. [cited 2019 Jun 14]. Available from: https://www.poxelpharma.com/en_us/product-pipeline/imeglimin-us-eu.
   Google Scholar
• Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab. 2012;14:852–858.
   PubMed Web of Science ®Google Scholar
• Dubourg J. Clinical evidence to support the safety and efficacy of imeglimin in various populations of patients with type 2 diabetes [Internet]. Barcelona; 2019. Available from: https://www.easd.org/virtualmeeting/home.html#!resources/clinical-evidence-to-support-the-safety-and-efficacy-of-imeglimin-in-various-populations-of-patients-with-type-2-diabetes
   Google Scholar
• Fouqueray P, Leverve X, Fontaine E, et al. Imeglimin - a new oral anti-diabetic that targets the three key defects of type 2 diabetes. J Diabetes Metab. 2011;02. doi: 10.4172/2155-6156.1000126
   Google Scholar
• Fouqueray F. Imeglimin improves vascular dysfunction in type 2 diabetes animal models. DIABETOLOG. 2016;59:S341.
   Google Scholar
• Hallakou-Bozec S, Bolze S, Kergoat M, et al. Imeglimin increases insulin secretion in response to glucose by a unique mechanism of action depending on NAD synthesis. Diabetes. 76th Scientific Sessions of the American Diabetes Association, ADA 2016. United States. 65 (Supplement 1) (pp A282). doi: 10.2337/db16-861-1374.
   Web of Science ®Google Scholar
• Hallakou-Bozec S, Bolze S, Kergoat M, et al. Imeglimin improves insulin sensitivity in an adult STZ rat model. Diabetes. 76th Scientific Sessions of the American Diabetes Association, ADA 2016. 65 (Supplement 1) (pp A314). doi: 10.2337/db16-861-1374.
   Google Scholar
• Hallakou-Bozec S, Kergoat M, Bolze S, et al. Imeglimin preserves beta cell function and mass in male zucker diabetic fatty rats. Endocr Pract. 14th Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease, WCIRDC. United States. 2017. 23 (1) (pp 32A).
   Google Scholar
• Lachaux M, Souille M, Remy-Jouet I, et al. Acute imeglimin treatment improves metabolic syndrome-related cardiac and coronary endothelial dysfunction in the zucker fa/fa rat. Eur Heart J. 2018. European Society of Cardiology Congress, ESC 2018 Germany. 39 (Supplement 1) (pp 484–485). doi: 10.1093/eurheartj/ehy565.P2500.
   Google Scholar
• Li J, Shirakawa J, Togashi Y, et al. Effects of imeglimin on insulin secretion, beta-cell proliferation, or apoptosis in mouse islets. J Diabetes Investig. 2018. Asia Islet Biology and lncretin Symposium, AIBIS 2018. South Korea. 9 (Supplement 1) (pp 12). doi: 10.1111/jdi.12937.
   Google Scholar
• Lablanche S, Tubbs E, Cottet-Rousselle C, et al. Imeglimin protects INS-1 cells and human islets against high glucose-and high fructose-induced cell death by inhibiting the mitochondrial PTP opening. Diabetes. 2018;67:81-OR.
   Web of Science ®Google Scholar
• Vial G, Chauvin M-A, Bendridi N, et al. Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes. 2015;64:2254–2264.
   PubMed Web of Science ®Google Scholar
• Perry RJ, Cardone RL, Petersen MC, et al. Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents. Am J Physiol Endocrinol Metab. 2016;311:E461–470.
   PubMed Web of Science ®Google Scholar
• Detaille D, Vial G, Borel A-L, et al. Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell Death Discov. 2016;2:15072.
   PubMed Web of Science ®Google Scholar
• Fouqueray P, Pirags V, Inzucchi SE, et al. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2013;36:565–568.
   PubMed Web of Science ®Google Scholar
• Fouqueray P, Pirags V, Diamant M, et al. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. Diabetes Care. 2014;37:1924–1930.
   PubMed Web of Science ®Google Scholar
• Pacini G, Mari A, Fouqueray P, et al. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17:541–545.
   PubMed Web of Science ®Google Scholar
• Fouqueray, Fouqueray. Dose-ranging study to determine the optimum dose for imeglimin, a novel treatment for type 2 diabetes. DIABETES. 2015;64:A301.
   Google Scholar
• Dubourg J, Ueki K, Watada H, et al. Imeglimin monotherapy in Japanese patients with type 2 diabetes: results from a randomised, 24-week, double-blind, placebo-controlled, phase IIb trial. Diabetologia. 2017. 53rd Annual Meeting of the European Association for the Study of Diabetes, EASD 2017. Portugal, 60 (1 Supplement 1) (pp S390–S391). doi: 10.1007/s00125-017-4350-z.
   Google Scholar
• Poxel SA Poxel and sumitomo dainippon pharma announce positive top-line results for imeglimin phase 3 trial (TIMES 1) in Japan for the treatment of type 2 diabetes [Internet]. [cited 2019 Jun 25]. Available from: https://www.poxelpharma.com/en_us/news-media/press-releases/detail/117/poxel-and-sumitomo-dainippon-pharma-announce-positive.
   Google Scholar
• Raczyńska ED, Gal J-F, Maria P-C, et al. Biguanide antidiabetic drugs: imeglimin exhibits higher proton basicity but smaller lithium-cation basicity than metformin in vacuo. ACS Omega. 2018;3:17842–17852.
   Web of Science ®Google Scholar
• Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60:1577–1585.
   PubMed Web of Science ®Google Scholar
• Poxel. Imeglimin - Japan/Asia [Internet]. 2019 [cited 2019 Jul 9]. Available from: https://www.poxelpharma.com/en_us/product-pipeline/imeglimin-japan.
   Google Scholar
• JAPIC Clinical Trials Information [Internet]. 2019 [cited 2019 Jul 9]. Available from: https://www.clinicaltrials.jp/.
   Google Scholar
• PMDA. Guideline for clinical evaluation of oral hypoglycemic agents [Internet]. 2010 [cited 2019 Jul 9]. Available from: http://www.pmda.go.jp/files/000153859.pdf.
   Google Scholar
• FDA. Guidance for industry diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [Internet]. 2008 [cited 2019 Jun 28]. Available from: https://www.fda.gov/media/71297/download.
   Google Scholar
• Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus [Internet]. 2012 [cited 2019 Jul 9]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-prevention-diabetes-mellitus_en.pdf.
   Google Scholar